Rimonabant + Placebo (for Rimonabant)

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Fatty Liver

Conditions

Fatty Liver

Trial Timeline

Feb 1, 2008 → Feb 1, 2009

NCT ID

NCT00577148

About Rimonabant + Placebo (for Rimonabant)

Rimonabant + Placebo (for Rimonabant) is a phase 3 stage product being developed by Sanofi for Fatty Liver. The current trial status is terminated. This product is registered under clinical trial identifier NCT00577148. Target conditions include Fatty Liver.

What happened to similar drugs?

6 of 11 similar drugs in Fatty Liver were approved

Approved (6) Terminated (2) Active (4)

🔄GODEX + PlaceboCelltrionPhase 3

✅Orlistat (Xenical)RocheApproved

✅Xenical, Pegasys, CopegusRocheApproved

✅atorvastatin + Vitamin EPfizerApproved

❌Rimonabant + Placebo (for Rimonabant)SanofiPhase 3

✅Testosterone Undecanoate + PlaceboBayerApproved

✅Clinolipid + IntralipidBaxterApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00577148	Phase 3	Terminated	Feb 1, 2008	Feb 1, 2009	Fatty Liver
NCT00576667	Phase 3	Terminated	Jan 1, 2008	Feb 1, 2009	Fatty Liver
NCT00478972	Phase 3	Terminated	Apr 1, 2007	Jan 1, 2009	Obesity
NCT00325650	Phase 3	Terminated	May 1, 2006	Mar 1, 2009	Prediabetic State
NCT00299325	Phase 3	Completed	Feb 1, 2006	Jul 1, 2008	Metabolic Syndrome
NCT00263042	Phase 3	Terminated	Dec 1, 2005	Apr 1, 2009	Cardiovascular Disease
NCT00228176	Phase 3	Terminated	Aug 1, 2005	Apr 1, 2009	Carotid Artery Plaque

Competing Products

20 competing products in Fatty Liver

See all competitors

Product	Company	Stage	Hype Score
Lanifibranor	Inventiva	Phase 2	29
Low Dose REN001 + High Dose REN001	OnKure Therapeutics	Phase 1	19
GODEX + Placebo	Celltrion	Phase 3	47
placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo	AstraZeneca	Phase 2	35
AZ compound	AstraZeneca	Phase 2	27
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo	AstraZeneca	Phase 2	35
AZD7503 Intervention	AstraZeneca	Phase 1	29
metformin	Merck	Phase 2/3	34
Efinopegdutide + Semaglutide + Placebo	Merck	Phase 2	35
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride	Merck	Phase 1	29
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL	Merck	Phase 2	35
LYS006 + Tropifexor	Novartis	Phase 2	27
LJN452	Novartis	Phase 1	29
LCQ908 + placebo	Novartis	Phase 2	35
Orlistat (Xenical)	Roche	Approved	43
Xenical, Pegasys, Copegus	Roche	Approved	43
Placebo + RO5093151	Roche	Phase 1	29
AMG 609 + Placebo	Amgen	Phase 1	29
Glucagon	Novo Nordisk	Pre-clinical	26
Blood samples	Novo Nordisk	Pre-clinical	18